Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
Titel:
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
Auteur:
Lancet, Jeffrey E. Cortes, Jorge E. Hogge, Donna E. Tallman, Martin S. Kovacsovics, Tibor J. Damon, Lloyd E. Komrokji, Rami Solomon, Scott R. Kolitz, Jonathan E. Cooper, Maureen Yeager, Andrew M. Louie, Arthur C. Feldman, Eric J.